The 2019 Nobel Prize in Physiology or Medicine was awarded to three physician scientists, Drs. William G. Kaelin, Jr., Peter Ratcliffe and Gregg Semenza, for their groundbreaking work revealing how cells sense and adapt to oxygen availability. Here, we summarize the history of their discoveries.
Oxygen is vital for all living organisms. During the course of evolution, animals have developed the ability to adapt to changes in the oxygen concentration on earth. However, it was unclear how animals can sense and adapt to changes in oxygen availability until around thirty years ago. The pioneering work performed by the laboratories of Drs. William Kaelin, Jr., Peter Ratcliffe and Gregg Semenza paved the way to understand the molecular mechanism of oxygen sensing. We herein summarize the major milestones in the history of research on the oxygen sensing pathway (Fig. 2) .
The journey started with the purification of erythropoietin (EPO), a glycoprotein hormone produced by the fetal liver and then by adult kidneys. The protein was purified in 1977 1 and the gene was cloned in 1985. 2 At that time, it was known that EPO was produced in response to a low blood oxygen concentration. However, it was not known how EPO was regulated by low oxygen. Semenza and his colleagues found that a region located on the 3' enhancer of EPO, currently known as the Hypoxia Response Element (HRE), was responsible for nuclear factor binding and EPO expression under hypoxia. 3 This finding was subsequently confirmed in the same year by Ratcliffe and his colleagues. 4 In addition, Ratcliffe and colleagues found that HRE DNA binding can occur in all cell types, including those not involved in EPO production, suggesting that this may be a general oxygen sensing mechanism that can regulate the expression of other genes that may be oxygen responsive, 5 including genes encoding glycolytic enzymes and the angiogenic factor, vascular endothelial growth factor (VEGF). 6, 7 However, the nuclear factor binding to the enhancers of EPO remained elusive. In 1995, Dr. Guang-Liang Wang and Dr. Bing-Hua Jiang, both working as postdoctoral fellows under Semenza, purified and cloned this transcription factor, which they named hypoxia inducible factor-1 (HIF-1). 8, 9 HIF-1 is composed of two subunits, the oxygen labile HIF-1a and the constitutively expressed HIF-1b (also called ARNT, aryl hydrocarbon receptor nuclear translocator). Despite the fact that the mRNA expression of both subunits typically remains constant under either normoxia or hypoxia, the HIF-1a protein was found to be induced and accumulate under hypoxia, suggesting that some type of posttranscriptional/post-translational modification(s) contribute to the regulation of HIF-1a at the protein level.
Kaelin's group at Harvard made major contributions to deciphering this regulatory mechanism. Based on his clinical experience as an oncologist, Kaelin was aware that most kidney tumors that lose expression of the von Hippel-Lindau (VHL) tumor suppressor are highly vascularized. When he and his group found that VHL forms a complex with Elongin B and C and CUL2, homologs of yeast ubiquitin ligase proteins, 10, 11 he hypothesized that the absence of VHL could lead to VEGF stabilization and subsequent increased vascularity. Indeed, he soon discovered that VHL deficiency led to upregulation of VEGF and other HIF targets, even under normoxia. 12 The E3 ubiquitin ligase activity of the VHL complex was subsequently demonstrated after Joan and Ronald Conaway collaborated with Kaelin to identify another essential protein called Rbx1, which is required for the ubiquitin ligase activity. 13, 14 It did not take long for both Kaelin and Ratcliffe to ascertain the molecular link between VHL and HIF. Indeed, in two back-to-back landmark papers published in 2001, 15, 16 they demonstrated that VHL binds HIF-1a under normoxia, but fails to do so under hypoxia, suggesting that VHL recognizes a modified form of HIF-1a.
This modification turned out to be prolyl hydroxylation on the proline 564 residue, which is essential for the recognition of HIF-1a by the VHL complex. Recognition of the modification leads to the ubiquitination and subsequent proteasomal degradation of HIF-1a. This breakthrough demonstrated that oxygen-dependent prolyl hydroxylation is key for mammalian oxygen sensing. However, this led to another question, namely, what was responsible for the HIF-1 oxygen-dependent hydroxylation. Ratcliffe, Kaelin (with the Conaways) and Steve McKnight all found the same answer using completely independent methods: HIF-1a hydroxylation is catalyzed by a family of prolyl-4-hydroxylases (PHDs) that are enzymatically inactive under hypoxia. 17e19 Ratcliffe, Semenza, and others had already shown that HIF-1 C-terminal transactivation domains were also subject to oxygen-dependent regulation, which altered the transcriptional activity of HIF-1 without affecting the protein's stability. 20, 21 Semenza and colleagues identified and characterized a protein that interacts with HIF-1 and impairs its transcriptional activity, which was accordingly named factor inhibiting HIF-1 (FIH-1). 22 Richard Bruick's group subsequently showed that FIH-1 is the asparaginyl hydroxylase of HIF-1, and this hydroxylation inhibits its ability to bind to transcriptional coactivators. 23 The discovery of HIF prolyl and asparaginyl hydroxylation completed the elegant network of oxygen-modulated regulation of HIF-1 activity. Interestingly, FIH-1 can be enzymatically active at a lower oxygen concentration than PHDs. 24 FIH-1 hydroxylates asparagine 803, which is located in the C-terminal transactivation domain of HIF-1a, thereby inhibiting HIF-1a transcriptional activity by preventing its interaction with transcriptional coactivators, including CBP/p300 23 Purifica on of HREbinding transcrip on factor, called HIF-1 (hypoxia inducible factor-1) [9] HIF-1 also induces the expression of the angiogenic vascular endothelia growth factor (VEGF) [7] HRE DNA binding ac vity is found also in cell types not producing EPO [5] HRE found in the enhancers of glycoly c enzyme genes [6] VHL forms a complex with Elongin B and C and CUL2, homologs of the yeast ubiqui n ligase proteins [10, 11] VHL deficiency causes HIF-regulated gene upregula on even in normoxia [12] HIF-1 is prolyl hydroxylated under normoxia, leading to its recogni on by VHL that ubiqui nates it for proteasomal degrada on [15, 16] HIF-1 hydroxyla on is performed by a family of prolyl-4hydroxylases [17] [18] [19] HIF-1 is also hydroxylated on asparagine residues, which inhibits its ability to bind to transcrip onal coac vators [23] Purifica on of human erythropoie n (EPO) [1] Cloning of the human EPO gene [2] Reprint permi ed by Science Bulle n complex, which leads to HIF-1a ubiquitination and subsequent proteasomal degradation (Fig. 3) .
In less than a decade, Kaelin, Ratcliffe and Semenza delineated the detailed molecular mechanism by which the oxygen sensing pathway works. It is important to point out that these three outstanding scientists worked independently and solved many puzzles from different perspectives: Kaelin started his line of research from his experiences in oncology and based on biochemical investigations; Ratcliffe's studies started from his role as a nephrologist, and Semenza utilized his expertise in medical genetics. Their Nobel prize-winning work embodies the importance of cross-disciplinary approaches in tackling critical questions in physiology and human diseases.
Importantly, their work opened up the important field of research focused on mammalian oxygen sensing. At present, there are close to 70 enzyme family members that may depend on oxygen for their functions besides prolyl hydroxylases. 25 In fact, some of the enzymes involved in epigenetic regulation, including KDM5A (also known as RBP2) histone demethylase, which identified by Kaelin and Yi Zhang, 26 were recently shown to be oxygen sensing enzymes. 27, 28 It remains to be determined how other enzymes would work in oxygen sensing, and if the effects of the various enzymes are synergistic, complementary or whether they lead to feedback inhibition. It is also important to note that there may be other prolyl hydroxylase substrates besides HIF. 29, 30 For example, HIF-2a inhibitors only showed a partial response in kidney cancer cell lines and patient-derived xenografts, 31, 32 suggesting that there are other VHL substrates. 29 Although research in this field will continue to expand for the foreseeable future, the findings have already been translated to the clinic. For example, a pan-prolyl hydroxylase inhibitor, Roxadustat, has just been approved in China for the treatment of anemia caused by kidney failure.
In summary, Drs. Kaelin, Ratcliffe and Semenza paved the road for understanding oxygen sensing and adaptability, and major efforts are currently underway to develop therapeutic strategies to treat human diseases such as anemia, coronary artery disease, inflammatory bowel diseases and cancer. 
